Work

Trc105 (Anti-Endoglin Antibody) in Combination with Bevacizumab (Bev) and As a Single Agent for Platinum Resistant Ovarian Cancer

Year: 2014

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu338.13

Authors: A.A. Garcia, V. Makker, D.L. Spitz, D.E. Matei, A.M. Nick, C.N. Landen, E.A. Alvarez, D.S. Mendelson, R.M. Strother, B.K. Seon, D. Alvarez, B.J. Adams, C.P. Theuer, M. Gordon

Institutions: University of Southern California, USC Norris Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Indiana University Indianapolis, Indiana University School of Medicine, The University of Texas MD Anderson Cancer Center, University of Alabama at Birmingham, University of California San Diego, Pinnacle Oncology Hematology, Roswell Park Comprehensive Cancer Center, Tracon Pharmaceuticals (United States)

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2263103728

FWCI:

Cites:

Cited by: 1

Related to: 10